JP2023549075A5 - - Google Patents
Info
- Publication number
- JP2023549075A5 JP2023549075A5 JP2023526226A JP2023526226A JP2023549075A5 JP 2023549075 A5 JP2023549075 A5 JP 2023549075A5 JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023549075 A5 JP2023549075 A5 JP 2023549075A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- nmosd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107182P | 2020-10-29 | 2020-10-29 | |
| US63/107,182 | 2020-10-29 | ||
| US202163143541P | 2021-01-29 | 2021-01-29 | |
| US63/143,541 | 2021-01-29 | ||
| US202163178286P | 2021-04-22 | 2021-04-22 | |
| US63/178,286 | 2021-04-22 | ||
| PCT/US2021/057443 WO2022094334A1 (en) | 2020-10-29 | 2021-10-29 | Use of an anti-cd19 antibody to treat autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549075A JP2023549075A (ja) | 2023-11-22 |
| JP2023549075A5 true JP2023549075A5 (enExample) | 2024-11-07 |
Family
ID=81384348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526226A Pending JP2023549075A (ja) | 2020-10-29 | 2021-10-29 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287114A1 (enExample) |
| EP (1) | EP4237447A4 (enExample) |
| JP (1) | JP2023549075A (enExample) |
| KR (1) | KR20230097118A (enExample) |
| AU (1) | AU2021368769A1 (enExample) |
| CA (1) | CA3197022A1 (enExample) |
| IL (1) | IL302294A (enExample) |
| MX (1) | MX2023004794A (enExample) |
| TW (1) | TW202233676A (enExample) |
| WO (1) | WO2022094334A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022006283A2 (en) * | 2020-06-30 | 2022-01-06 | Viela Bio, Inc. | Methods of treating neuromyelitis optica spectrum disorder |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| AU2020263418A1 (en) * | 2019-04-24 | 2021-11-11 | Viela Bio, Inc. | Use of an anti-CD19 antibody to treat autoimmune disease |
| WO2022006283A2 (en) * | 2020-06-30 | 2022-01-06 | Viela Bio, Inc. | Methods of treating neuromyelitis optica spectrum disorder |
-
2021
- 2021-10-29 AU AU2021368769A patent/AU2021368769A1/en active Pending
- 2021-10-29 TW TW110140391A patent/TW202233676A/zh unknown
- 2021-10-29 MX MX2023004794A patent/MX2023004794A/es unknown
- 2021-10-29 IL IL302294A patent/IL302294A/en unknown
- 2021-10-29 CA CA3197022A patent/CA3197022A1/en active Pending
- 2021-10-29 EP EP21887669.6A patent/EP4237447A4/en active Pending
- 2021-10-29 JP JP2023526226A patent/JP2023549075A/ja active Pending
- 2021-10-29 KR KR1020237018007A patent/KR20230097118A/ko active Pending
- 2021-10-29 WO PCT/US2021/057443 patent/WO2022094334A1/en not_active Ceased
-
2023
- 2023-04-19 US US18/303,303 patent/US20230287114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foster et al. | Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study | |
| US8835487B2 (en) | Method of treating multiple sclerosis | |
| JP2022553329A5 (enExample) | ||
| JP2022529743A5 (enExample) | ||
| WO2021041773A1 (en) | Methods for the treatment of thyroid eye disease | |
| JP2023549075A5 (enExample) | ||
| WO2022187510A1 (en) | Methods for the treatment of thyroid eye disease | |
| TW202227131A (zh) | 帕金森氏症之治療 | |
| Sokmen et al. | A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: Successfully treated with anti-CD20 monoclonal antibody | |
| JP2023548005A (ja) | 抗トランスサイレチン抗体およびその使用方法 | |
| Bhat et al. | Intravenous daclizumab for recalcitrant ocular inflammatory disease | |
| US20230406928A1 (en) | Methods of treating neuromyelitis optica spectrum disorder | |
| IL302383A (en) | Method of safe administration of anti-tau antibody | |
| JP2024540294A5 (enExample) | ||
| Bromfield et al. | Phenytoin withdrawal and seizure frequency | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| Kes et al. | Therapeutic Plasma Exchange in the Neurologic Intensive Care Setting: Recommendation for Clinical Practice | |
| Harris et al. | Acute demyelinating disorders of the central nervous system | |
| Ha et al. | Clinical preoperative and postoperative symptoms of exotropia | |
| WO2022185224A1 (en) | Treatment and/or reduction of occurrence of migraine | |
| KR101226605B1 (ko) | 질병의 치료 | |
| Singh et al. | Targeted steroid delivery for myelin oligodendrocyte glycoprotein antibody-associated rare optic neuritis: Clinical outcome and review literature | |
| TW202317181A (zh) | 治療視神經脊髓炎譜系障礙之方法 | |
| HK40087593A (zh) | 治疗视神经脊髓炎谱系障碍的方法 | |
| Mehndiratta et al. | Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy |